Witness Testimony

Dr. Laura Braden testified as a molecular biologist with expertise in genomics, transcriptomics, immunology, and molecular systems. She presented a detailed slideshow outlining her concerns regarding the design, manufacturing consistency, and regulatory oversight of COVID-19 mRNA injections.
Her testimony focused on the molecular composition of the products, including the presence of plasmid DNA sequences, promoters (including SB40), possible antibiotic resistance genes, and variability in mRNA and spike protein fragments. She stated that proper pharmaceutical quality control and assurance standards require batch consistency and contaminant screening, and testified that, in her view, these standards were not adequately met.
Braden described the injections as gene therapy products rather than conventional vaccines and raised concerns regarding potential genomic integration, persistence in the body, biodistribution variability, and unknown long-term effects. She stated that manufacturing variability could result in inconsistent biological outcomes between injections.
She also addressed broader issues including the timeline of vaccine development compared to historical norms, the justification of mandates, suppression of early treatment discussions, and the classification of the pandemic response. In her conclusion, she expressed the opinion that the mRNA products were not safe, not necessary, and did not meet expected pharmaceutical standards.